• Bristol Myers Squibb released Phase 4 data on switching adult outpatients with schizophrenia from oral atypical antipsychotics to Cobenfy monotherapy.
• Results were presented at 2026 Schizophrenia International Research Society congress running March 25-29 in Florence.
• Trial enrolled 105 patients, testing 2-week vs 4-week cross-titration while up-titrating Cobenfy to 125/30 mg twice daily.
• Patients stayed clinically stable through week 8, with PANSS total scores remaining below baseline; no discontinuations were tied to lack of efficacy.
• About 86% completed treatment; all-cause discontinuation ran 15.1% in slower switch group vs 13.5% in faster group, with no serious treatment-emergent adverse events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260326860298) on March 28, 2026, and is solely responsible for the information contained therein.